Mark D. Mcdade's most recent trade in Tourmaline Bio Inc was a trade of 16,800 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tourmaline Bio Inc | Mark D. Mcdade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 16,800 | 16,800 | - | - | Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Mark D. Mcdade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Mark D. Mcdade | Director | Purchase of securities on an exchange or from another person at price $ 32.50 per share. | 29 Jan 2024 | 100,000 | 448,431 | - | 32.5 | 3,250,000 | Common Stock |
| Icosavax Inc | Mark D. Mcdade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Icosavax Inc | Mark D. Mcdade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 22,278 | 22,278 | - | - | Stock Option (Right to Buy) | |
| Icosavax Inc | Mark D. Mcdade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 5,543 | 55,786 | - | 0 | Common Stock | |
| Talaris Therapeutics Inc | Mark D. Mcdade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 14,501 | 14,501 | - | - | Stock Option (Right to Buy) | |
| Icosavax Inc | Mark D. Mcdade | Director | Purchase of securities on an exchange or from another person at price $ 7.10 per share. | 01 Apr 2022 | 42,225 | 50,243 | - | 7.1 | 299,798 | Common Stock |